Glenmede Trust CO Na Cyma Bay Therapeutics, Inc. Transaction History

Glenmede Trust CO Na

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$12.63 - $24.47 $107,620 - $208,508	-8,521 Reduced 22.49%	29,373 $693,000
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $411,528 - $667,692	37,894 New	37,894 $564,000
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $1,564 - $2,465	-273 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.32 - $7.24 $906 - $1,976	273 New	273 $1,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.